Information Provided By: 
Fly News Breaks for December 11, 2019
SGEN
Dec 11, 2019 | 12:53 EDT
Piper Jaffray analyst Joseph Catanzaro says Seattle Genetics' tucatinib data from the HER2CLIMB study in late-line breast cancer were "very positive, but largely in-line with expectations." At minimum, these data support the tucatinib triplet regimen as future standard of care for late-line ER2+ metastatic breast cancer patients with brain mets, Catanzaro tells investors in a research note. He keeps an Overweight rating on Seattle Genetics with a $120 price target.
News For SGEN From the Last 2 Days
There are no results for your query SGEN
